Agios Pharmaceuticals
AGIO
152 hedge funds and large institutions have $2.64B invested in Agios Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 63 increasing their positions, 39 reducing their positions, and 24 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 39
46% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 24
7% more funds holding
Funds holding: 142 → 152 (+10)
15% less capital invested
Capital invested by funds: $3.1B → $2.64B (-$461M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
21% less call options, than puts
Call options by funds: $19.4M | Put options by funds: $24.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$138M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$61.9M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$38.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.1M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$23.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$344M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$16.3M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$15.9M |
| 4 |
CCI
Columbus Circle Investors
|
-$13.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$10.3M |
AGIO Hedge Fund Activity: Q1 2015 in Review
152 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2015, worth a combined $2.64B — down 15% from $3.1B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new AGIO positions and 24 closed out — a net gain of 11 holders — while 63 added to existing stakes and 39 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $138M. The largest seller was Third Rock Ventures, exiting entirely with an estimated $344M sold.
- 152 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2015, up from 142 in Q4 2014.
- Funds reported $2.64B of Agios Pharmaceuticals stock for Q1 2015, down 15% quarter-over-quarter.
- 35 funds opened new Agios Pharmaceuticals positions in Q1 2015 and 24 closed out, a net change of +11 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2015 was Wellington Management Group, an estimated $138M added.
- The largest Agios Pharmaceuticals seller in Q1 2015 was Third Rock Ventures, an estimated $344M sold.
Based on aggregated 13F filings for Q1 2015.